Takeshi Nakaura1,2, Yasunori Nagayama3,4, Masafumi Kidoh3,4, Shinichi Nakamura3,4, Tomohiro Namimoto4, Kazuo Awai5, Kazunori Harada6, Yasuyuki Yamashita4. 1. Diagnostic Radiology, Amakusa Medical Center, Kameba 854-1, Amakusa, Kumamoto, 863-0046, Japan. kff00712@gmail.com. 2. Department of Diagnostic Radiology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan. kff00712@gmail.com. 3. Diagnostic Radiology, Amakusa Medical Center, Kameba 854-1, Amakusa, Kumamoto, 863-0046, Japan. 4. Department of Diagnostic Radiology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan. 5. Department of Diagnostic Radiology, Graduate School of Medical Science, Hiroshima University, Hiroshima, Japan. 6. Department of Surgery, Amakusa Medical Center, Amakusa, Japan.
Abstract
PURPOSE: To evaluate the feasibility of a 20 % reduced contrast dose hepatic arterial phase (HAP) CT for hypervascular hepatocellular carcinoma (HCC) with 100 kVp. MATERIALS AND METHODS: The study included 97 patients with hypervascular HCC who underwent dynamic CT, including HAP scanning. The 54 patients had an estimated glomerular filtration rate (eGFR) of ≥60 were scanned with our conventional 120 kVp protocol. The other 43 patients (eGFR < 60) underwent scans using a tube voltage of 100 kVp and a 20 % reduced contrast dose. We compared the estimated effective dose, image noise, tumor-liver contrast (TLC), and contrast-to-noise ratio (CNR) in the hepatic arterial phase between the two groups using the Student's t test. RESULTS: Estimated effective dose and image noise were not significantly different between these groups (p = 0.67 and p = 0.20, respectively). The TLC and CNR were significantly higher for the 100 kVp protocol than for the 120 kVp protocol (52.2 HU ± 17.4 vs 40.8 HU ± 18.6, p < 0.01 and 6.8 ± 2.6 vs 5.5 ± 2.4, p = 0.01, respectively). CONCLUSION: For hepatic arterial phase CT of hypervascular HCC, 100 kVp scan allows a 20 % reduction in the contrast dose without reduction in image quality compared with a standard 120 kVp CT protocol.
PURPOSE: To evaluate the feasibility of a 20 % reduced contrast dose hepatic arterial phase (HAP) CT for hypervascular hepatocellular carcinoma (HCC) with 100 kVp. MATERIALS AND METHODS: The study included 97 patients with hypervascular HCC who underwent dynamic CT, including HAP scanning. The 54 patients had an estimated glomerular filtration rate (eGFR) of ≥60 were scanned with our conventional 120 kVp protocol. The other 43 patients (eGFR < 60) underwent scans using a tube voltage of 100 kVp and a 20 % reduced contrast dose. We compared the estimated effective dose, image noise, tumor-liver contrast (TLC), and contrast-to-noise ratio (CNR) in the hepatic arterial phase between the two groups using the Student's t test. RESULTS: Estimated effective dose and image noise were not significantly different between these groups (p = 0.67 and p = 0.20, respectively). The TLC and CNR were significantly higher for the 100 kVp protocol than for the 120 kVp protocol (52.2 HU ± 17.4 vs 40.8 HU ± 18.6, p < 0.01 and 6.8 ± 2.6 vs 5.5 ± 2.4, p = 0.01, respectively). CONCLUSION: For hepatic arterial phase CT of hypervascular HCC, 100 kVp scan allows a 20 % reduction in the contrast dose without reduction in image quality compared with a standard 120 kVp CT protocol.
Entities:
Keywords:
100 kVp; Contrast induced nephropathy; Hypervascular hepatocellular carcinoma; Low kilo voltage CT; Renal dysfunction
Authors: L Gruberg; G S Mintz; R Mehran; G Gangas; A J Lansky; K M Kent; A D Pichard; L F Satler; M B Leon Journal: J Am Coll Cardiol Date: 2000-11-01 Impact factor: 24.094